Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 2/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26964190 | 0.94 | TP53 (0.49) | TP53HPGDSYKAURKBINCENP | |
| SCHEMBL16334229 | 0.85 | TP53 (0.44) | TP53HPGDSYKL3MBTL1PKM | |
| SCHEMBL16334791 | 0.83 | FFAR4 (0.49) | TP53HPGDCLK4SYKAURKB | |
| SCHEMBL26964234 | 0.82 | TP53 (0.53) | TP53HPGDL3MBTL1PKMALDH1A1 | |
| SCHEMBL16334065 | 0.81 | TP53 (0.52) | TP53HPGDL3MBTL1PKMALDH1A1 | |
| SCHEMBL2099509 | 0.81 | TP53 (0.52) | TP53HPGDL3MBTL1PKMALDH1A1 | |
| SCHEMBL16334749 | 0.80 | SYK (0.46) | TP53HPGDCLK4SYKAURKB | |
| SCHEMBL10414873 | 0.79 | ALDH1A1 (0.58) | TP53L3MBTL1PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL26964197 | 0.77 | TP53 (0.48) | TP53HPGDL3MBTL1PKMALDH1A1 | |
| SCHEMBL16334706 | 0.77 | FFAR4 (0.53) | HPGDCLK4SYKAURKBINCENP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105392777-B | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2020-09-22 | — | — | CN | disclosed |
| EP-3013796-B9 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEMICAL LTD (KR) | 2020-07-01 | — | — | EP | disclosed |
| EP-3628661-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEM, LTD. (KR) | 2020-04-01 | — | — | EP | disclosed |
| US-10221138-B2 | Biaryl derivatives as GPR120 agonists | LG CHEM, LTD. (KR) | 2019-03-05 | — | — | US | disclosed |
| US-20160168096-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2016-06-16 | — | — | US | disclosed |
| EP-3013796-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG Life Sciences Ltd. (KR) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014209034-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168096-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | GPR119, GLP1R, GIPR | TP53 4800/4885HPGD 2858/4885CLK4 3077/4885 |
| US-10221138-B2 | Biaryl derivatives as GPR120 agonists | GPR119, GLP1R, GIPR | TP53 4800/4885HPGD 2858/4885CLK4 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.